Shares of Cytek Biosciences declined 6.7% after the company’s Q1 results failed to fully reassure investors, primarily due to revenue deceleration in key regions, a cautious outlook, and shipment delays that pressured growth outside the U.S.

• Total Q1 revenue grew 6% year-over-year to $44.1 million but was weighed down by a 7% revenue decline in EMEA and a 13% drop in APAC including China.
• U.S. revenue was a bright spot with a 32% increase to $24.4 million, driven by repeat sales to academic and biopharma customers and continued adoption of Aurora flagship instruments.
• Recurring revenue (service and reagents) reached $18.4 million on a trailing 12-month basis, representing 35% of total revenue and growing 19% year-over-year.
• Instrument unit volume rose 9% year-over-year, aided by solid uptake of the Aurora Evo system, which contributed 8% revenue growth in the analyzer category.
• EMEA softness arose from Middle East conflict disruptions and end-of-quarter shipment delays, while APAC weakness reflected tough prior-year comparisons and timing shifts in China orders.